These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38442006)

  • 1. Clinical and basic research implications of the article 'IGF-1 axis changes with ADT and docetaxel in metastatic prostate cancer'.
    Heidegger I; Culig Z
    Endocr Relat Cancer; 2024 May; 31(5):. PubMed ID: 38442006
    [No Abstract]   [Full Text] [Related]  

  • 2. Addition of Docetaxel to Androgen Receptor Axis-targeted Therapy and Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis.
    Roy S; Sayyid R; Saad F; Sun Y; Lajkosz K; Ong M; Klaassen Z; Malone S; Spratt DE; Wallis CJD; Morgan SC
    Eur Urol Oncol; 2022 Oct; 5(5):494-502. PubMed ID: 35811293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis.
    Botrel TE; Clark O; Lima Pompeo AC; Horta Bretas FF; Sadi MV; Ferreira U; Borges Dos Reis R
    PLoS One; 2016; 11(6):e0157660. PubMed ID: 27308831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
    Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
    Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Docetaxel or abiraterone in combination with androgen deprivation therapy for metastatic prostate cancer].
    Hammerer P; Manka L
    Urologe A; 2019 Oct; 58(10):1185-1197. PubMed ID: 31127324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative clinical effects and cost-effectiveness of maximum androgen blockade, docetaxel with androgen deprivation therapy and ADT alone for the treatment of mHSPC in China.
    Liu M; Qu S; Liu Y; Yao X; Jiang W
    J Comp Eff Res; 2019 Aug; 8(11):865-877. PubMed ID: 31476895
    [No Abstract]   [Full Text] [Related]  

  • 7. Recent trend of androgen deprivation therapy in newly diagnosed prostate cancer patients: Comparing between high- and middle-income Asian countries.
    Lim J; Onozawa M; Saad M; Ong TA; ; ; ; Malek R; Akaza H
    Cancer Sci; 2021 Jun; 112(6):2071-2080. PubMed ID: 33738901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-term outcomes of risk-adapted upfront docetaxel administration in patients with metastatic hormone-sensitive prostate cancer: a multicenter prospective study in Japan.
    Muto Y; Narita S; Hatakeyama S; Maita S; Chiba S; Kubo K; Aoyama Y; Ito R; Takahashi Y; Takahashi S; Nakamura K; Honma N; Sato H; Koizumi A; Igarashi R; Okane K; Ishida T; Horikawa Y; Kumazawa T; Akihama S; Shimoda J; Suzuki T; Ohyama C; Habuchi T
    Med Oncol; 2021 Mar; 38(4):37. PubMed ID: 33713196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of Metastatic Hormone-Sensitive Prostate Cancer: Is Docetaxel Needed?
    Kartolo A; Tannock IF; Vera Badillo FE
    J Clin Oncol; 2022 Nov; 40(31):3573-3575. PubMed ID: 35724342
    [No Abstract]   [Full Text] [Related]  

  • 10. SYSTEMIC TRIPLE THERAPY IN METASTATIC HORMONE SENSITIVE PROSTATE CANCER (MHSPC).
    Omrčen T
    Acta Clin Croat; 2022 Oct; 61(Suppl 3):81-85. PubMed ID: 36938560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
    Gravis G; Fizazi K; Joly F; Oudard S; Priou F; Esterni B; Latorzeff I; Delva R; Krakowski I; Laguerre B; Rolland F; Théodore C; Deplanque G; Ferrero JM; Pouessel D; Mourey L; Beuzeboc P; Zanetta S; Habibian M; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Labourey JL; Machiels JP; El Kouri C; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Soulie M
    Lancet Oncol; 2013 Feb; 14(2):149-58. PubMed ID: 23306100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [mHSPC-Therapie mit Apalutamid/ADT].
    Bismarck E; Hammerer P; Merseburger AS; Schrader AJ
    Oncol Res Treat; 2020; 43 Suppl 2():6-12. PubMed ID: 32434198
    [No Abstract]   [Full Text] [Related]  

  • 13. Commentary on "Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial." Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, Latorzeff I, Delva R, Krakowski I, Laguerre B, Rolland F, Théodore C, Deplanque G, Ferrero JM, Pouessel D, Mourey L, Beuzeboc P, Zanetta S, Habibian M, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Labourey JL, Machiels JP, El Kouri C, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Soulie M, Medical Oncology and Biostatistics, Institut Paoli-Calmettes, Marseille, France. Lancet Oncol 2013;14(2):149-58 [Epub 2013 Jan 8].
    Trump DL
    Urol Oncol; 2013 Nov; 31(8):1845. PubMed ID: 24210084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: A Systematic Review and Network Meta-analysis.
    Mandel P; Hoeh B; Wenzel M; Preisser F; Tian Z; Tilki D; Steuber T; Karakiewicz PI; Chun FKH
    Eur Urol Focus; 2023 Jan; 9(1):96-105. PubMed ID: 36058809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment situation in metastastic Castration Naive Prostate Cancer (mCRPC) and the implications on clinical routine].
    Wülfing C; Bögemann M; Goebell PJ; Hammerer P; Machtens S; Pfister D; Schwentner C; Steuber T; von Amsberg G; Schostak M
    Urologe A; 2019 Sep; 58(9):1066-1072. PubMed ID: 31041460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of efficacy of androgen-receptor-axis-targeted therapies in patients with metastatic castration-sensitive prostate cancer: A systematic review and meta-analysis.
    Buonerba C; Ferro M; Dolce P; Crocetto F; Verde A; Lucarelli G; Scafuri L; Facchini S; Vaia A; Marinelli A; Terracciano D; Montella L; Longo N; Imbimbo C; Mirone V; Di Lorenzo G; De Placido S; Sonpavde G
    Crit Rev Oncol Hematol; 2020 Jul; 151():102992. PubMed ID: 32474391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of patients with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC) in Belgium: a real world data analysis.
    Lambert E; Hollebosch S; van Praet C; Van Bruwaene S; Duck L; De Roock W; van Wambeke S; Ghysel C; Ameye F; Schatteman P; Vandenbroucke F; Sautois B; Baekelandt F; Ost D; Fransis K; Filleul B; Remondo C; Wynendaele W; Bamelis B; Logghe P; Vergauwe E; Denies E; Joniau S; Lumen N
    Acta Clin Belg; 2022 Dec; 77(6):897-905. PubMed ID: 34789066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of docetaxel versus nonsteroidal antiandrogen with androgen deprivation therapy for high-volume metastatic hormone-sensitive prostate cancer: a propensity score-matched analysis.
    Yanagisawa T; Kimura T; Hata K; Narita S; Hatakeyama S; Mori K; Sano T; Otsuka T; Iwamoto Y; Enei Y; Nakazono M; Sakanaka K; Iwatani K; Matsukawa A; Atsuta M; Nishikawa H; Tsuzuki S; Miki J; Habuchi T; Ohyama C; Shariat SF; Egawa S
    World J Urol; 2023 Aug; 41(8):2051-2062. PubMed ID: 35596809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of Adding Docetaxel to Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer in Korean Real-World Practice.
    Park K; Kim JY; Park I; Shin SH; Lee HJ; Lee JL
    Yonsei Med J; 2023 Feb; 64(2):86-93. PubMed ID: 36719015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of baseline serum IL-8 on metastatic hormone-sensitive prostate cancer outcomes in the Phase 3 CHAARTED trial (E3805).
    Harshman LC; Wang VX; Hamid AA; Santone G; Drake CG; Carducci MA; DiPaola RS; Fichorova RN; Sweeney CJ
    Prostate; 2020 Dec; 80(16):1429-1437. PubMed ID: 32949185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.